Does visceral adiposity have an effect on the survival outcomes of the patients with endometrial cancer?
adiposity
disease-specific survival
endometrial cancer
progression-free survival
subcutaneous adipose tissue
visceral adipose tissue
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
15
08
2020
revised:
22
09
2020
accepted:
16
10
2020
pubmed:
17
11
2020
medline:
22
6
2021
entrez:
16
11
2020
Statut:
ppublish
Résumé
Endometrial cancer is the most common cancer of the female reproductive tract in the developed countries. There are many risk factors defined for the development of endometrial cancer, including obesity. We aimed to evaluate the significance of adiposity on the survival outcomes of the patients with endometrial cancer. The patients diagnosed with endometrial cancer and underwent surgery between April 2009 and October 2017 were retrospectively reviewed. The visceral adipose tissue and subcutaneous adipose tissue volumes were measured at the level of umbilicus on single-slice magnetic resonance imaging. Visceral adiposity index was calculated. Patients were compared regarding their clinical, demographical, pathologic and survival characteristics. Patients divided into low visceral adiposity (≤0.265, group 1) and high visceral adiposity (>0.265, group 2). A total of 186 patients were included in this retrospective study. There was no significant difference in terms of the demographical, clinical and tumor characteristics of the patients, except age, menopausal status, subcutaneous adipose tissue and visceral adipose tissue. Although no significant difference in progression-free survival and disease-specific survival was noted between groups (P = 0.181), more patients in group 2 died because of endometrial cancer as statistically significant (P = 0.024). Disease-specific survival showed a significant difference between groups according to the log-rank test. Visceral adiposity tissue is a significant and reliable prognostic indicator for endometrial cancer prognosis. Women diagnosed with endometrial cancer should be informed about the deleterious effects of visceral adiposity on disease-specific survival.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
560-569Informations de copyright
© 2020 Japan Society of Obstetrics and Gynecology.
Références
Lewin SN, Herzog TJ, Barrena Medel NI et al. Comparative performance of the 2009 international federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol 2010; 116: 1141-1149.
Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95 (Suppl 1): S105-S143.
Galaal K, Al Moundhri M, Bryant A et al. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev 2014; (5): CD010681.
Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209.
Setiawan VW, Yang HP, Pike MC et al. Type I and II endometrial cancers: Have they different risk factors? J Clin Oncol 2013; 31: 2607-2618.
Felix AS, Weissfeld JL, Stone RA et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control 2010; 21: 1851-1856.
Schoen RE, Tangen CM, Kuller LH et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999; 91: 1147-1154.
Gillen J, Mills KA, Dvorak J et al. Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab. Gynecol Oncol Rep 2019; 30: 100502.
Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009; 114: 121-127.
Cree IA, White VA, Indave BI, Lokuhetty D. Revising the WHO classification: Female genital tract tumours. Histopathology 2020; 76: 151-156.
FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet 2014; 125: 97-98.
Colombo N, Creutzberg C, Amant F et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Int J Gynecol Cancer 2016; 26: 2-30.
Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9: 671-675.
Williams BA, Mandrekar JN, Mandrekar SJ et al. Finding Optimal Cutpoints for Continuous Covariates with Binary and Time-to-Event Outcomes. Technical Report Series #79. Rochester, MN: Department of Health Sciences Research, Mayo Clinic, 2006.
Everett E, Tamimi H, Greer B et al. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2003; 90: 150-157.
Mauland KK, Trovik J, Wik E et al. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. Br J Cancer 2011; 104: 921-926.
Reeves KW, Carter GC, Rodabough RJ et al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative. Gynecol Oncol 2011; 121: 376-382.
Grignol VP, Smith AD, Shlapak D, Zhang X, del Campo SM, Carson WE. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy. Surg Oncol 2015; 24: 353-358.
Okamura A, Watanabe M, Mine S et al. Clinical impact of abdominal fat distribution on prognosis after Esophagectomy for esophageal squamous cell carcinoma. Ann Surg Oncol 2016; 23: 1387-1394.
Clark W, Siegel EM, Chen YA et al. Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation. J Am Coll Surg 2013; 216: 1070-1081.
Mauland KK, Eng Ø, Ytre-Hauge S et al. High visceral fat percentage is associated with poor outcome in endometrial cancer. Oncotarget 2017; 8: 105184-105195.
Arem H, Irwin ML. Obesity and endometrial cancer survival: A systematic review. Int J Obes (Lond) 2013; 37: 634-639.
Ye S, Wen H, Jiang Z, Wu X. The effect of visceral obesity on clinicopathological features in patients with endometrial cancer: A retrospective analysis of 200 Chinese patients. BMC Cancer 2016; 16: 209.
Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc 2012; 71: 181-189.
Nakamura K, Hongo A, Kodama J, Hiramatsu Y. Fat accumulation in adipose tissues as a risk factor for the development of endometrial cancer. Oncol Rep 2011; 26: 65-71.